Research programme: RNA inhibitors - Pfizer/Roche
Alternative Names: Research programme: RNA inhibitors - Roche/WyethLatest Information Update: 16 Jul 2016
At a glance
- Originator Pfizer; Santaris Pharma
- Developer Pfizer; Roche
- Class Antisense oligonucleotides
- Mechanism of Action Antisense RNA inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Undefined in Denmark (Parenteral)
- 05 Jan 2011 Pfizer and Santaris expand their collaboration
- 12 Jan 2009 Early research in Undefined indication in Denmark (parenteral)